Polychemotherapy of Gastric Carcinoma

  • H. Wilke
  • P. Preusser
  • W. Achterrath
  • H.-J. Schmoll
  • U. Fink
  • H. Poliwoda
Conference paper


Gastric carcinoma is the second leading cause of death due to malignant neoplasias in the Federal Republic of Germany; 28 deaths per 100,000 inhabitants are recorded every year.1


Gastric Cancer Clin Oncol Gastric Carcinoma Advanced Gastric Cancer Remission Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Causes of Death 1983, in Federal Office of Statistics, Wiesbaden: Gesundheitswesen, Series 12. Stuttgart, W. Kohlhammer, 1984, p. 12.Google Scholar
  2. 2.
    UICC: Spiesse B, Hermanek P, Scheibe O, et al (eds): TNM-Atlas. Berlin-HeidelbergNew York, Springer, 1985, p. 90.Google Scholar
  3. 3.
    Diehl JT, Herrmann RE, Cooperman AM, et al: Gastric carcinoma. A ten year review. Ann Surg 1983; 198: 9.PubMedCrossRefGoogle Scholar
  4. 4.
    Bengmark S. Jeppson B: Staging of liver metastases, in Wess L, Gilberg HA (eds): Liver Metastases. Boston, GK Hall, 1982, p. 268.Google Scholar
  5. 5.
    Koyama Y, Sugimachi K. Soejima K: Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 1981; 5: 241.CrossRefGoogle Scholar
  6. 6.
    Nekajima T, Harashima S, Hirata M: Prognostic and therapeutic values of peritoneal cytology in gastric cancer. Acta Cytol 1978; 22: 225.Google Scholar
  7. 7.
    De Lisi V, Cocconi G, Tonato M, et al: Randomized comparison of 5-FU alone or combined with carmustine, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC). Cancer Treat Rep 1986; 70: 481.PubMedGoogle Scholar
  8. 8.
    O’Connell MJ: Current status of chemotherapy for advanced pancreatic and gastric cancer. J Clin Oncol 1985; 3: 1032.PubMedGoogle Scholar
  9. 9.
    Borchard F, Sons HU: Klassifizierung des Magenkarzinoms aus pathologisch-anatomischer Sicht. Therapiewoche 1985; 35: 161.Google Scholar
  10. 10.
    Clarke JS, Cruze K, El Farra S, et al: The natural history and results of surgical therapy for carcinoma of the stomach. An analysis of 250 cases. Am J Surg 1961; 102: 143.PubMedCrossRefGoogle Scholar
  11. 11.
    Dupont JB, Lee JR, Burton GR, et al: Adenocarcinoma of the stomach: review of 1497 cases. Cancer 1978; 41: 941.PubMedCrossRefGoogle Scholar
  12. 12.
    Walther H: Krebsmetastasen. Basel, Schwabe, 1948, p 363.Google Scholar
  13. 13.
    Warren S: Studies on tumor metastasis: IV. Metastases of cancer of the stomach. N Engl J Med 1933; 209: 825.CrossRefGoogle Scholar
  14. 14.
    Warwick M: Analysis of one hundred and seventy-six cases of carcinoma of the stomach submitted to autopsy. Ann Surg 1928; 88: 216.PubMedCrossRefGoogle Scholar
  15. 15.
    Moertel CG, Lavin PT: Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979; 63: 1863.PubMedGoogle Scholar
  16. 16.
    The Gastrointestinal Tumor Study Group: Phase II-III chemotherapy studies in advanced gastric cancer. Cancer Treat Rep 1979; 63: 1871.Google Scholar
  17. 17.
    Bruckner HW, Lokich JJ, Stablein DM: Studies of Bakers antifol, methotrexate and Razoxane in advanced gastric cancer. A Gastrointestinal Tumor Study Group Report. Cancer Treat Rep 1982; 66: 1713.PubMedGoogle Scholar
  18. 18.
    Aabo K, Pedersen H, Rorth M: Cisplatin in the treatment of advanced gastric carcinomas: a phase II study. Cancer Treat Rep 1985; 69: 449.PubMedGoogle Scholar
  19. 19.
    Beer M, Cocconi G, Ceci G, et al: A phase II study of cisplatin in advanced gastric cancer. Eur J Cancer Clin Oncol 1983; 19: 717.PubMedCrossRefGoogle Scholar
  20. 20.
    Kantarjian H, Ajani JA, Karlin DA: Cis-diaminodichloroplatinum (II) chemotherapy for advanced adenocarcinoma of the upper gastrointestinal tract. Oncology 1985; 42: 69.PubMedCrossRefGoogle Scholar
  21. 21.
    Lacave AJ, Wils H, Bleiberg E, et al: Advanced and chemotherapy-resistant gastric cancer (GC): benefit of additional MeCCNU (Me) and evaluation of CDDP (P), abstract. EORTC Symposium on Gastrointestinal Tract Cancer, Heidelberg, May 29–30, 1986.Google Scholar
  22. 22.
    Lacave AJ, Wils J, Diaz-Rubio E, et al: Phase II study of cisplatin (DDP) in chemotherapy resistant carcinoma of the stomach. Cancer Chemother Pharmacol 1985; 14 (suppl): 39.Google Scholar
  23. 23.
    Perry MC, Green MR, Mick R, et al: Cisplatin in patients with gastric cancer: a cancer and leukemia group B phase II study. Cancer Treat Rep 1986; 70: 415.PubMedGoogle Scholar
  24. 24.
    Preusser P, Achterrath W, Niederle N, et al: Cisplatin. Arzneimitteltherapie 1985; 2: 50.Google Scholar
  25. 25.
    Bedikian AY, Chen TT, Khankhanian N, et al: The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol 1984; 2: 305.PubMedGoogle Scholar
  26. 26.
    Bleiberg H: Prognostic significance of pathological staging in gastrointestinal tumors. Eur J Cancer Clin Oncol 1985; 21: 655.PubMedCrossRefGoogle Scholar
  27. 27.
    Bruckner HW, Stablein DM: Sites of treatment failure: Gastrointestinal Tumor Study Group analyses of gastric, pancreatic, colorectal trials. Cancer Treat Rep 1983; 2: 199.Google Scholar
  28. 28.
    Lavin PT, Bruckner HW, Plaxe SC: Studies in prognostic factors relating to chemotherapy for advanced gastric cancer. Cancer 1982; 50: 2016.Google Scholar
  29. 29.
    MacDonald JS, Schein PS, Woolley PV, et al: 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination-chemotherapy for advanced gastric cancer. Ann Intern Med 1980; 93: 533.PubMedGoogle Scholar
  30. 30.
    Queisser W, Flechtner H, Heim ME, et al: 5-Fluorouracil, 4-epidoxorubicin, and mitomycin C (FEM) for advanced gastric carcinoma, a phase II trial. J Cancer Res Clin Oncol 1986; 111 (suppl): 85.CrossRefGoogle Scholar
  31. 31.
    Kim RH, Huh K, Ahn Y, et al: BCNU, cisplatin and 5-fluorouracil polychemotherapy in advanced gastric cancer. Proc ASCO 1985; 4: 95.Google Scholar
  32. 32.
    Kim RH, Kim CS: Chemotherapy of advanced gastric cancer with mitomycin C, BCNU, cisplatin and 5-fluorouracil in combination. Proc ASCO 1986; 5: 78.Google Scholar
  33. 33.
    Schein PS, Coombes RC, Chilvers C: For the international adjuvant trial in gastric cancer. A controlled trial of FAM (5-FU, doxorubicin, and mitomycin C) chemotherapy as adjuvant treatment for resected gastric carcinoma: an interim report. Proc ASCO 1986; 5: 79.Google Scholar
  34. 34.
    Galiano R, McCracken JD, Chen T: Adjuvant chemotherapy with 5-fluorouracil, Adriamycin, and mitomycin (FAM) in gastric cancer. Proc ASACO 1983; 2: 114.Google Scholar
  35. 35.
    Imanaga H, Nakazato H: Results of surgery for gastric cancer and effect of adjuvant mitomycin-C on cancer recurrence. World J Surg 1977; 1: 213.CrossRefGoogle Scholar
  36. 36.
    Koyama Y: The current status of chemotherapy for gastric cancer in Japan with special emphasis on mitomycin-C. Rec Res Cancer Res 1978; 63: 135.Google Scholar
  37. 37.
    Asakawa H, Otawa K, Watari J: High energy x-ray therapy for stomach carcinoma, second report: the evaluation of radiotherapy for the early and the inoperable stomach carcinoma. Nippon Acta Radiol 1971; 31: 505.PubMedGoogle Scholar
  38. 38.
    Asakawa H, Takeda T: High energy x-ray therapy of gastric carcinoma. J Jap Soc Cancer Ther 1973; 8: 362.Google Scholar
  39. 39.
    Childs DS, Moertel CG, Holbrook MA, et al: Treatment of unresectable adenocarcinoma of the stomach with a combination of 5-fluorouracil and radiation. Am J Roentgenol 1986; 102: 541.Google Scholar
  40. 40.
    Falkson G: Halogenated pyrimidines as radiopotentiators in the treatment of stomach cancer. Prog Biochem Pharmacol 1965; 1: 695.Google Scholar
  41. 41.
    Falkson G, Falkson HC::Fluorouracil and radiotherapy in gastrointestinal cancer. Lancet 1969; 2: 1252.PubMedCrossRefGoogle Scholar
  42. 42.
    Gastrointestinal Tumor Study Group: A combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Cancer 1982; 49: 1771.CrossRefGoogle Scholar
  43. 43.
    Gunderson LL, Hoskins B, Cohen AM, et al: Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys 1983; 9: 965.PubMedCrossRefGoogle Scholar
  44. 44.
    Haas L, Vaitkevicius V, Bukowski R, et al: Southwest Oncology Group (SWOG) pilot study of radiotherapy (R) + 5-fluorouracil (F) + Adriamycin = mitomycin C (M),in patients with minimal residual gastric cancer, abstract. Proc ASCO 1980;342:C-439.Google Scholar
  45. 45.
    Schein PS, Smith FP, Dritschillo A, et al: Phase I-II trial of combined modality FAM plus split-course radiation (FAM-RT-FAM) for locally advanced gastric and pancreatic cancer: a Mid-Atlantic Oncology Program Study, abstract. Proc ASCO 1983;126:C-491.Google Scholar
  46. 46.
    Lagunova IG, Cybulskij BA, Minerva OD, et al: Aufeinander folgende Strahlentherapie mit einem 24-meV Betatron and Chemotherapie mit Fluorouracil zur Behandlung von Kranken mit fortgeschrittenem Krebs des oberen Magenabschnittes. Radiobiol Radiother 1978; 13: 307.Google Scholar
  47. 47.
    Levi JA, Fox RM, Tattersall MH, et al: Analysis of a prospective randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. J Clin Oncol 1986; 4: 1348.PubMedGoogle Scholar
  48. 48.
    Gelber RD, Zelen M: Planning and reporting of clinical trials, in Calabresi PC, Schein PC, Rosenberg S (eds): Medical Oncology. New York, Macmillan, 1985, p 406.Google Scholar
  49. 49.
    Design and conduct of clinical trials, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: Principles & Practice of Oncology. Philadelphia, JB Lippincott, 1985, p 329.Google Scholar
  50. 50.
    Cullinan SA, Moertel CG, Fleming TR, et al: A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985; 12: 2061.Google Scholar
  51. 51.
    Kolaric K, Potrebica V, Stanovnik M: Controlled phase III clinical study of 4-epidoxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. Oncology 1986; 43: 73.PubMedCrossRefGoogle Scholar
  52. 52.
    Kovach JS, Moertel CG, Schutt AJ: A controlled trial of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 1974; 33: 563.PubMedCrossRefGoogle Scholar
  53. 53.
    Gastrointestinal Tumor Study Group: Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. Cancer 1982; 49: 1116.CrossRefGoogle Scholar
  54. 54.
    Wilke H, Preusser P, Fink U, et al: Preoperative “neoadjuvant” chemotherapy with etoposide/Adriamycin/cisplatin (EAP) in local advanced gastric cancer. Proc ECCO 1987; 4: 32.Google Scholar
  55. 55.
    Behre W, Brömsen J, Harstrick A, et al: Antitumor activity of anthracyclines in human gastric cancer xenografts depending on time scheduling. Blut 1987; 55: 224.Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 1989

Authors and Affiliations

  • H. Wilke
  • P. Preusser
  • W. Achterrath
  • H.-J. Schmoll
  • U. Fink
  • H. Poliwoda

There are no affiliations available

Personalised recommendations